A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor

作者：Faranoush M; Abolghasemi H^*; Mahboudi F; Toogeh Gh; Karimi M; Eshghi P; Managhchi M; Hoorfar H; Dehdezi B Keikhaei; Mehrvar A; Khoeiny B; Vaziri B; Kamyar K; Heshmat R; Baghaeipour M R; Mirbehbahani N B; Fayazfar R; Ahmadinejad M; Naderi M

来源：Clinical and Applied Thrombosis/Hemostasis, 2016, 22(2): 184-190.

DOI：10.1177/1076029614555902

• Inhibitor
• Hemophilia A
• rFVIIa
• Novoseven
• Aryoseven

Introduction: This study compared the efficacy of Aryoseven with Novoseven to control bleeding episodes in patients with hemophilia A with inhibitors.
Methods: Sixty-six patients were randomized into 2 groups, with 4 consecutive block randomization. These groups received Aryoseven and Novoseven dosages of 90 to 120 g/kg intravenously every 2 hours.
Results: Median (interquartile range) level of factor VIII (FVIII) inhibitor in groups A and B was 15.0 and 19.0 Bethesda Unit (BU) preadministration. Bleeding onset in group A was 1246 1104 minutes and in group B was 2301 +/- 1693 minutes (P = .311). The Kavakli global response scores and treatment success rate was comparable in both the groups. The side effects in groups A (9.7%) and B (2.9%) were comparable.
Conclusion: Biosimilar recombinant activated FVII is found to be as effective as Novoseven in the treatment of acute joint bleeding in patients with hemophilia with inhibitors. Its usage will decrease the gaps in hemophilia.

• 出版日期2016-3